Please use this identifier to cite or link to this item:
Title: The benefits of combination therapy with esomeprazole and rebamipide in symptom improvement in reflux esophagitis: An international multicenter study
Authors: Su Jin Hong
Soo Heon Park
Jeong Seop Moon
Woon Geon Shin
Jae Gyu Kim
Yong Chan Lee
Dong Ho Lee
Jae Young Jang
Jae J. Kim
Hang Lak Lee
Sang Woo Lee
Young Hwangbo
Jianming Xu
Bangmao Wang
Zhanxiong Xue
Fei Liu
Yaozong Yuan
Somchai Leelakusolvong
Frederick Dy
Soonchunhyang University, College of Medicine
The Catholic University of Korea, College of Medicine
Inje University Paik Hospital
Hallym University, College of Medicine
Chung-Ang University, College of Medicine
Yonsei University College of Medicine
Seoul National University Bundang Hospital
Kyung Hee University
SungKyunKwan University, School of Medicine
HanYang University, College of Medicine
Korea University Medical Center
Anhui Medical University
Tianjin Medical University
Wenzhou Medical University
Tongji University
Shanghai Jiao Tong University
Mahidol University
University of Santo Tomas Hospital
Keywords: Medicine
Issue Date: 1-Nov-2016
Citation: Gut and Liver. Vol.10, No.6 (2016)
Abstract: Background/Aims: To investigate the effects of esomeprazole and rebamipide combination therapy on symptomatic improvement in patients with reflux esophagitis. Methods: A total of 501 patients with reflux esophagitis were randomized into one of the following two treatment regimens: 40 mg esomeprazole plus 300 mg rebamipide daily (combination therapy group) or 40 mg esomeprazole daily (monotherapy group). We used a symptom questionnaire that evaluated heartburn, acid regurgitation, and four upper gastrointestinal symptoms. The primary efficacy end point was the mean decrease in the total symptom score. Results: The mean decreases in the total symptom score at 4 weeks were estimated to be -18.1±13.8 in the combination therapy group and -15.1±11.9 in the monotherapy group (p=0.011). Changes in reflux symptoms from baseline after 4 weeks of treatment were -8.4±6.6 in the combination therapy group and -6.8±5.9 in the monotherapy group (p=0.009). Conclusions: Over a 4-week treatment course, esomeprazole and rebamipide combination therapy was more effective in decreasing the symptoms of reflux esophagitis than esomeprazole monotherapy.
ISSN: 19762283
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.